Pre-surgery radiation plus an anti-cancer drug for soft tissue sarcoma
Treatments studied
Part of Cancer clinical trials.
This Phase 2 trial tests whether giving radiation before surgery, along with anlotinib and penpulimab, can improve treatment for localized soft tissue sarcoma. It may help shrink or control the tumor before conservative surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 years or older
- You have a confirmed diagnosis of soft tissue sarcoma (in the arm/leg or trunk) that can be treated before surgery
- The tumor can be measured/assessed on scans
- You can safely receive radiotherapy and anlotinib (and have your suitability reviewed by the study team)
- You agree to use effective contraception during the study
- You understand the study and sign informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a shorter course of radiation before surgery is effective for soft tissue sarcomas in certain locations. It aims to make treatment more convenient while maintaining good results.
This trial tests a new approach for high-risk soft tissue sarcoma of the arm, leg, or trunk. Before surgery, you would receive chemotherapy combined with local hyperthermia (a treatment that gently heats the tumor area) to see if this can improve outcomes.
This trial studies whether adding a chemotherapy medicine called trabectedin to targeted radiation can help control certain soft tissue sarcomas. It focuses on specific cancer types and locations, aiming to shrink tumors while keeping radiation safe for nearby healthy organs.
This trial tests a combination of radiation therapy and two drugs (anlotinib and penpulimab) given before surgery for soft tissue sarcoma. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests combining anlotinib (a targeted therapy), doxorubicin (chemotherapy), and radiation given before surgery to shrink high-grade soft tissue sarcomas. The goal is to make the tumor easier to remove and improve outcomes.
This Phase 1/2 trial tests whether combining radiation with two targeted/immune medicines can shrink or control high-risk soft tissue sarcoma and improve outcomes. It may help patients whose tumors are large, hard to fully remove, or have come back after prior treatment.
Hear when a new Trunk trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.